Trachoma Risk Down 91% Since 2002: What the WHO Figures Mean

Facebook ↗WhatsApp ↗

Originally published 2019-07-10.

In June 2019 the World Health Organization reported one of the quieter success stories in global health: the number of people living in areas where they are at risk of blindness from trachoma had fallen from about 1.5 billion in 2002 to just over 142 million. That is a drop of roughly 91 percent in 17 years. Over the same period, the number of people needing surgery for the late, blinding stage of the disease fell from 7.6 million to 2.5 million, a cut of about 68 percent.

Those figures, presented at a meeting of the WHO Alliance for the Global Elimination of Trachoma by 2020 (GET2020), show what a long, coordinated public health campaign can achieve. They also need a little explaining. Here is what trachoma is, what "at risk" really means, how the decline happened, and where things stand now.

The 2019 Estimate of People at Risk From Trachoma

What trachoma is

Trachoma is an eye disease caused by the bacterium Chlamydia trachomatis, and it is the world's leading infectious cause of blindness. It passes from person to person through discharge from the eyes and nose, carried on fingers, shared towels, clothing and bedding, and by flies that feed around children's faces. Young children are the main carriers, and most spread happens inside families.

One infection is usually mild and looks like conjunctivitis. The danger comes from repeated infections over many years. Each bout inflames the inner surface of the upper eyelid and leaves scar tissue. Over time that scarring pulls the eyelid inward until the eyelashes scrape the eyeball, a painful stage called trachomatous trichiasis. Every blink damages the cornea, and without treatment the cornea clouds over and sight is lost for good.

The disease is ancient. Descriptions of it go back to Egypt more than two thousand years ago, it was common in 19th-century European cities and army barracks, and immigrants arriving at Ellis Island in New York were screened for it. Better living conditions largely removed it from Europe and North America in the early 20th century. Today it persists where poverty, crowding and poor access to water and toilets overlap, above all in parts of Africa.

What the 91 percent figure means

The headline number does not count infections cured. It measures how many people live in districts where trachoma is still common enough that public health action is needed. When a district's surveys show that infection has fallen below WHO thresholds and stays there, the people living in it are no longer counted as at risk.

So the fall from 1.5 billion to about 142 million means that hundreds of millions of people now live in places where the disease is no longer a public health problem. It does not mean every individual case has disappeared, and the estimates themselves were refined over the years as more districts were surveyed, so part of the change reflects better data as well as real progress.

The surgery figure is more direct. Fewer people needing operations for trichiasis means fewer people in pain and fewer heading toward blindness, and it reflects both successful surgery campaigns and fewer new cases reaching the late stage.

How the decline was achieved

In 1993 the WHO adopted a four-part plan known by the acronym SAFE:

  • Surgery to correct inturned eyelids in people with trichiasis, often a short procedure done by trained nurses or eye-care workers in local clinics.
  • Antibiotics, mainly a single oral dose of azithromycin given to whole communities at once, which clears infection and cuts transmission. The drug manufacturer, Pfizer, donates it to elimination programmes through the International Trachoma Initiative.
  • Facial cleanliness, because clean faces in children mean less discharge for hands and flies to spread.
  • Environmental improvement, especially access to water and toilets, which reduces both the dirt that spreads infection and the flies that breed in exposed faeces.

The strategy works because it attacks every link in the chain at once: it treats the people already damaged, clears the bacteria from communities, and changes the conditions that let the infection come back.

Money and the Accelerate programme

Funding has been a big part of the story. At the Global Citizen Festival: Mandela 100 in Johannesburg in December 2018, a group of donors pledged 105 million US dollars to Accelerate, a programme managed with Sightsavers and designed to speed up elimination in several of the hardest-hit countries. The backers named at the time included the UK's Department for International Development, Virgin Unite, the Children's Investment Fund Foundation, ELMA Philanthropies and the Bill & Melinda Gates Foundation, through The Audacious Project.

Programmes like this pay for surgeons and outreach teams, mass drug distribution, the mapping surveys that show where trachoma remains, and the follow-up surveys that prove it has gone.

Where things stand now

Progress has continued since 2019. According to the WHO's current trachoma fact sheet, about 92 million people lived in endemic areas as of March 2026, and the disease remained a public health problem in parts of 29 countries. By September 2026, 33 countries had been validated by the WHO as having eliminated trachoma as a public health problem, including Morocco, Oman, Mexico, China, Ghana, Nepal, India, Pakistan, Egypt, Iraq, Senegal, Mali, Malawi and Australia.

The remaining burden is heavy for those who carry it. The WHO estimates that about 1.9 million people are blind or visually impaired because of trachoma, and women are blinded up to four times as often as men, largely because they spend more time caring for young children, who carry the infection. In 2025, 47.4 million people received antibiotics for trachoma, and nearly 99,000 had corrective eyelid surgery.

The GET2020 deadline was missed, as was common for disease goals delayed by the COVID-19 pandemic, and elimination targets now sit within the WHO's 2021 to 2030 road map for neglected tropical diseases.

Why trachoma is called a neglected tropical disease

Trachoma is one of the WHO's neglected tropical diseases (NTDs), a group of conditions that also includes leprosy, river blindness (onchocerciasis), soil-transmitted worm infections and others. They share a pattern: they mostly affect the poorest communities, they receive little commercial research attention, and they trap families in poverty by causing disability rather than quick death.

That is what makes the trachoma figures encouraging. They show that a disease of poverty can be pushed back with a clear strategy, donated medicines, local health workers and patient investment in water and sanitation. The final stretch is often the hardest, because the last affected areas tend to be remote, insecure or very poor, but the direction of travel over two decades has been clear.

Sources: WHO, Trachoma fact sheet; Jackie Marchildon, Global Citizen (27 June 2019); Trachoma (Wikipedia). Embedded post: Global Citizen Impact on Twitter/X.

COMMENTS